Inhibitor Therapeutics (INTI) Treasury Shares (2018 - 2019)
Inhibitor Therapeutics' (INTI) quarterly Treasury Shares came in at $4.5 million in Q4 2019, up 123.21% YoY from $2.0 million in Q4 2018, and up 123.21% on a QoQ basis from $2.0 million in Q4 2018.
Inhibitor Therapeutics (INTI) Treasury Shares (2018 - 2019) Analysis & Trends
Inhibitor Therapeutics (INTI) has 2 years of Treasury Shares data on file, last reported at $4.5 million in Q4 2019.
- Quarterly Treasury Shares rose 123.21% year-over-year to $4.5 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $4.5 million (up 123.21% YoY) and the FY2019 annual result came in at $4.5 million, up 123.21% from the prior year.
- Treasury Shares advanced to $4.5 million in Q4 2019, from $2.0 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $5.8 million in Q3 2018 to a low of $2.0 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 4.50 Mn |
| Dec 31, 2019 | 4.50 Mn |
| Dec 31, 2018 | 2.02 Mn |
| Dec 31, 2018 | 2.02 Mn |
| Sep 30, 2018 | 5.80 Mn |
| Sep 30, 2018 | 5.80 Mn |